| Literature DB >> 32715815 |
Maria Queralt Salas1,2,3, Shruti Prem1,2, Mats Remberger4, Wilson Lam1,2, Dennis Dong Hwan Kim1,2, Fotios Vasilios Michelis1,2, Zeyad Al-Shaibani1,2, Armin Gerbitz1,2, Jeffrey Howard Lipton1,2, Auro Viswabandya1,2, Rajat Kumar1,2, Deepali Kumar5, Jonas Mattsson1,2, Arjun Datt Law1,2.
Abstract
We explore risk factors and impacts of post-transplant EBV-Reactivation (EBV-R) and PTLD in 270 patients that underwent RIC alloHCT using ATG-PTCy and cyclosporine for GVHD prophylaxis. Twenty-five (12%) patients had probable (n = 7) or proven (n = 18) PTLD. Patients were managed with reduction of immunosuppression and 22 with weekly rituximab (375 mg/m2 IV). ORR was 84%; 8 (32%) recipients died, and one-year OS and NRM of patients with PTLD was 59.7% and 37%, respectively. One hundred seventy-two (63.7%) recipients had EBV-R. One-year OS and RFS of patients with EBV-R were 68.2% and 60.6%, and of EBV-Negative patients were 62.1% and 50.1%, respectively. High incidence but low mortality of EBV-R and PTLD was documented. EBV-R induced a protective effect on RFS in multivariable analysis (HR 0.91, p = .011). Therefore, EBV-R may have a protective effect on RFS in this setting. Further research is necessary to evaluate the interplay of EBV-R, immune reconstitution, and post-transplant outcomes.Entities:
Keywords: ATG; Epstein-Barr Virus; PTCy; PTLD; alloHCT; reduced intensity conditioning
Mesh：
Year: 2020 PMID： 32715815 DOI： 10.1080/10428194.2020.1797010
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022